Litigation Details for Lexmark International, Inc. v. Impression Products, Inc. (Fed. Cir. 2014)

« Back to Dashboard

Lexmark International, Inc. v. Impression Products, Inc. (Fed. Cir. 2014)

Docket		Date Filed	2014-07-14
Court	Court of Appeals for the Federal Circuit	Date Terminated	2017-07-10
Cause		Assigned To
Jury Demand		Referred To
Patents	11,007,139
Link to Docket	External link to docket

Details for Lexmark International, Inc. v. Impression Products, Inc. (Fed. Cir. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-14				External link to document

Lexmark International v. Impression Products, Inc. (14-1617): Patent Exhaustion, International Sales, and Generic IP Strategy

Last updated: September 30, 2026

The U.S. Supreme Court’s decision in Lexmark International, Inc. v. Impression Products, Inc., No. 14-1617, established that an authorized sale of a patented product exhausts the patent owner’s rights in that particular item, even when the sale includes a contractual restriction against resale or reuse. The Court also held that an authorized foreign sale exhausts U.S. patent rights in the product unless another legal basis prevents resale.

The June 30, 2017, decision rejected the Federal Circuit’s restrictive exhaustion rules and materially expanded the ability of purchasers, refurbishers, importers, and downstream competitors to resell or modify patented products. The ruling is a leading authority on patent exhaustion, post-sale restrictions, international arbitrage, remanufacturing, and patent-based channel control. [1]

What was the Lexmark v. Impression Products dispute about?

Lexmark manufactured and sold toner cartridges protected by multiple U.S. patents. It offered two cartridge programs:

1. A regular cartridge sold at a higher price.
2. A “Return Program” cartridge sold at a discount subject to a single-use restriction and a requirement that the cartridge be returned to Lexmark.

Impression Products acquired empty Lexmark cartridges, including cartridges originally sold in the United States and cartridges first sold abroad. It refilled and resold those cartridges in the United States.

Lexmark sued Impression Products for patent infringement. It argued that:

• The Return Program restrictions prevented patent exhaustion after domestic sales.
• Foreign sales did not exhaust Lexmark’s U.S. patent rights.
• Impression Products’ remanufacturing and resale therefore infringed Lexmark’s patents.

The dispute reached the Supreme Court through two Federal Circuit questions concerning domestic post-sale restrictions and international patent exhaustion.

Case identification

Item	Detail
Case	Lexmark International, Inc. v. Impression Products, Inc.
Supreme Court docket	No. 14-1617
Decision date	June 30, 2017
Citation	581 U.S. 152; 137 S. Ct. 1523
Lower court	U.S. Court of Appeals for the Federal Circuit
Technology	Toner cartridges and printer consumables
Patent issue	Patent exhaustion
Decision author	Chief Justice John Roberts
Result	Federal Circuit reversed

What did the Supreme Court hold in Lexmark?

The Court held that an authorized sale exhausts the patent owner’s patent rights in the specific article sold. That rule applies in both domestic and international transactions.

Domestic sales

A patentee cannot use patent law to impose post-sale restrictions on a product after selling it. Lexmark’s single-use and no-resale terms could be enforceable as contractual obligations, but they could not preserve a patent infringement claim against a downstream purchaser.

The Court treated patent exhaustion as a limit on the patent grant itself. Once the patentee sells the item, the buyer obtains the authority to use or resell that item free from the patentee’s infringement claims.

The Court distinguished between:

• Contract law, which may enforce a promise made by the buyer; and
• Patent law, which no longer controls the particular article after an authorized sale.

The ruling did not invalidate all post-sale restrictions. It limited the remedy available for breach. A patentee may pursue a contractual claim against a party bound by the restriction, but cannot rely on the restriction to assert patent infringement against downstream users or resellers. [1]

Foreign sales

The Court also held that an authorized sale abroad exhausts U.S. patent rights in the sold product. The Patent Act does not contain a geographic restriction that would preserve U.S. patent rights after an authorized foreign sale.

The decision rejected the Federal Circuit’s prior rule that a foreign sale exhausted U.S. patent rights only if the patentee expressly authorized that result. The Court reasoned that patent exhaustion follows the sale of the article and does not depend on the geographic location of the transaction.

A foreign sale therefore can create a lawful supply source for importation, resale, or remanufacturing in the United States, subject to other legal restrictions such as contract, trademark, customs, regulatory, or product-safety laws.

How did the Supreme Court’s ruling change patent exhaustion law?

Before Lexmark, the Federal Circuit applied two rules that gave patent owners greater control over downstream channels:

Issue	Federal Circuit approach	Supreme Court approach
Domestic sale with restriction	Restriction could prevent exhaustion	Sale exhausts patent rights; restriction may remain contractual
Authorized foreign sale	No exhaustion absent express authorization	Authorized sale exhausts U.S. patent rights
Downstream resale	Could support patent infringement under certain restrictions	Generally outside patent infringement control after exhaustion
Remanufacturing	Potential infringement if patent rights survived sale	Permitted for the sold article unless separate rights apply
Commercial leverage	Patent remedies could reinforce channel restrictions	Contract remedies are the principal enforcement tool

The Court’s analysis relied on the common-law principle against restraints on alienation and prior exhaustion decisions involving patented products. It also aligned patent exhaustion more closely with the Supreme Court’s international exhaustion analysis in Kirtsaeng v. John Wiley & Sons, Inc., although the decision emphasized that patent and copyright law are distinct statutory regimes. [1, 2]

What patent litigation issues were resolved in Lexmark?

The Supreme Court resolved two legal questions.

Can a patentee sue for infringement after a restricted domestic sale?

No. An authorized domestic sale exhausts the patentee’s patent rights in the specific product, even if the purchaser agreed to a single-use, no-resale, or return-to-manufacturer condition.

The restriction may create a breach-of-contract claim if the purchaser accepted the contractual terms. The contract claim depends on ordinary contract principles, including privity, governing law, damages, and available remedies.

Can a patentee sue for infringement after an authorized foreign sale?

No. An authorized foreign sale exhausts U.S. patent rights in the article sold. The purchaser or downstream reseller does not need separate authorization from the U.S. patent owner to import and sell that article in the United States.

The decision does not eliminate all controls over foreign distribution. A company may still use:

• Contract restrictions against direct counterparties.
• Trademark rights against confusing or misleading branding.
• Trade secret rights involving refurbishment processes.
• Regulatory controls applicable to the product.
• Customs and import restrictions unrelated to patent exhaustion.
• Separate patents covering new components or later manufacturing steps.

What was the litigation timeline in Lexmark v. Impression Products?

Date	Event
2010	Impression Products began acquiring used Lexmark cartridges and selling remanufactured cartridges.
2012	Lexmark sued Impression Products in the U.S. District Court for the Southern District of Ohio.
2013	The district court dismissed Lexmark’s claims involving cartridges first sold abroad but allowed claims involving domestic Return Program cartridges to proceed.
February 2016	The Federal Circuit, sitting en banc, ruled for Lexmark on both exhaustion issues.
September 2016	The Supreme Court granted certiorari.
December 2016	The Supreme Court heard oral argument.
June 30, 2017	The Supreme Court reversed the Federal Circuit and ruled for Impression Products on both questions.

The Supreme Court’s judgment returned the case for further proceedings consistent with its exhaustion ruling. The core patent-infringement theory based solely on the domestic sales restrictions and foreign sales could not survive under the Court’s holding.

What did Lexmark mean for remanufacturing and aftermarket competition?

The decision strengthened the aftermarket position for products that are sold rather than merely licensed. A purchaser that lawfully obtains a patented article generally may:

• Use the article.
• Resell the article.
• Import the article after an authorized foreign sale.
• Repair the article.
• Refurbish the article.
• Replace consumable components.
• Modify the article, subject to limits imposed by other patents and laws.

The ruling is particularly relevant to cartridges, medical devices, industrial equipment, automotive parts, electronics, diagnostic instruments, and other products with active secondary markets.

The exhaustion principle is product-specific. It does not give a remanufacturer unrestricted freedom to make new copies of a patented product. A company may repair or refurbish the sold item, but it may infringe if it reconstructs a new patented article or manufactures a separately patented component.

Repair versus reconstruction

The distinction remains fact-intensive:

• Repair preserves the identity of the original article.
• Reconstruction may create a new article that practices the patent.
• Replacing a spent component may be permissible if it restores the original product.
• Manufacturing a new patented component may create infringement exposure.

After Lexmark, companies must analyze the patent claims covering the original product, replacement components, manufacturing process, and refurbishment method separately.

How strong is the patent exhaustion precedent after Lexmark?

The decision is a strong Supreme Court precedent because it resolved both domestic and international exhaustion in a single case and rejected an en banc Federal Circuit rule. Courts generally treat the following propositions as established:

1. Patent exhaustion is triggered by an authorized sale.
2. Exhaustion applies regardless of a contractual resale restriction.
3. Exhaustion applies to authorized foreign sales.
4. Patent exhaustion is tied to the particular article sold.
5. Patent law cannot be used to enforce a post-sale restriction against downstream parties.
6. Contract law may remain available against a party that accepted the restriction.

The principal litigation uncertainty is not whether exhaustion exists, but whether the transaction was authorized and whether the accused conduct concerns the same article that was sold.

Issues that remain litigable

Issue	Continuing legal question
Authorization	Did the patentee or an authorized licensee make the sale?
Article identity	Is the accused product the same item sold by the patentee?
Reconstruction	Did refurbishment create a new patented article?
Component patents	Does a replacement part practice a separate patent?
License structure	Was the transaction a sale or a restricted license?
Contract scope	Is the downstream party bound by the restriction?
Foreign transaction	Was the foreign sale authorized?
Parallel patents	Do later-issued or separate patents cover the modified product?

What are the commercial implications of Lexmark for drug and medical-device companies?

Lexmark is not a pharmaceutical case, and it did not involve an active pharmaceutical ingredient, biologic, generic drug, biosimilar, FDA approval, Orange Book listing, Paragraph IV certification, or Hatch-Waxman litigation. Its principles nevertheless affect life-sciences businesses that sell patented products or components.

Medical devices and diagnostic platforms

Device manufacturers cannot automatically use patent infringement claims to block resale of an authorized device. This is relevant to:

• Surgical instruments.
• Infusion pumps.
• Diagnostic analyzers.
• Imaging equipment.
• Continuous glucose monitors.
• Laboratory consumables.
• Catheters and disposable assemblies.
• Device cartridges and test strips.

Companies seeking channel control may need contracts, service agreements, software access controls, trademark enforcement, or separate patents covering replacement components.

Drug delivery systems

A patented inhaler, injector, autoinjector, cartridge, pump, or other delivery device may be subject to exhaustion after an authorized sale. The exhaustion analysis may differ for:

• A device sold with a drug.
• A disposable delivery component.
• A refill cartridge.
• A separately sold replacement part.
• A product supplied under a license rather than sold.
• A combination product covered by multiple patents.

The sale of a finished drug does not automatically exhaust patents covering a separately manufactured device or a later-made replacement component.

Generic and biosimilar entry

Lexmark does not eliminate the need to analyze:

• Orange Book-listed patents.
• Patent term expiration.
• Paragraph IV certifications.
• Patent litigation under 35 U.S.C. § 271(e)(2).
• Patent claims covering formulations or methods of treatment.
• Biosimilar patents and the Biologics Price Competition and Innovation Act.
• Manufacturing-process patents.
• Device patents associated with combination products.

Its direct effect is narrower: once a patented article has been authorizedly sold, the patent owner generally cannot invoke patent infringement to control resale of that same article.

Does Lexmark affect formulation patents and method-of-use patents?

The decision does not eliminate formulation or method-of-use rights.

Formulation patents

An authorized sale of a drug product may exhaust patent rights in that specific product. It does not necessarily exhaust separate rights covering:

• A new formulation made after the sale.
• A manufacturing process used to make a replacement batch.
• A separately patented excipient combination.
• A new dosage form.
• A replacement device component.
• A process used to alter the product.

Method-of-use patents

Method-of-use patents remain enforceable against conduct that practices the claimed method. Exhaustion of a sold product does not automatically authorize every use of that product.

For example, a purchaser may own a sold patented device but still face infringement issues if it actively practices a separate patented treatment method. The analysis depends on claim scope, inducement, contributory infringement, authorization, and the relationship between the product sale and the claimed method.

What is the status of Paragraph IV challenges after Lexmark?

Lexmark did not alter the statutory Paragraph IV framework. A generic applicant still may certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The patent owner may still sue under the Hatch-Waxman statute, and a timely suit may trigger the statutory 30-month stay.

The decision may have indirect relevance where a company seeks to commercialize refurbished or previously sold medical products rather than manufacture a new drug product. It does not provide a defense to a Paragraph IV infringement claim involving an unexhausted patent claim covering a new formulation, manufacturing method, or later-made product.

What is the FDA regulatory status of Lexmark?

There is no FDA exclusivity, Orange Book, New Drug Application, abbreviated new drug application, biologic license application, or biosimilar approval associated with Lexmark. The dispute concerned printer cartridges and patent law, not FDA-regulated drug approval.

For life-sciences diligence, the case should be classified as a general patent-exhaustion authority rather than a pharmaceutical exclusivity precedent.

Which companies and industries were affected by Lexmark?

The decision had direct commercial significance for:

• Original equipment manufacturers.
• Cartridge remanufacturers.
• Parts distributors.
• Repair businesses.
• Refurbishment companies.
• Parallel importers.
• Used-equipment dealers.
• Industrial equipment operators.
• Medical-device aftermarket suppliers.

The ruling reduced the ability of patent owners to divide markets solely through patent infringement claims. It did not prevent differentiated pricing, territorial contracts, selective distribution, or downstream service models, but it shifted enforcement toward contract and non-patent rights.

What generic launch and parallel-import risks exist after Lexmark?

For patented physical products, the main risks are:

Risk	Effect after Lexmark
Domestic resale	Patent infringement claim generally unavailable after authorized sale
Foreign-source importation	U.S. patent claim generally unavailable after authorized foreign sale
Unlicensed new manufacture	Still potentially infringing
Replacement components	Separate component patents may apply
Reconstruction	May constitute manufacture of a new patented article
Contract breach	May remain actionable against a contracting party
Trademark misuse	May create separate liability
Regulatory noncompliance	Unaffected by patent exhaustion
Product liability	Unaffected by patent exhaustion
Trade secret misuse	Unaffected by patent exhaustion

The decision therefore creates a resale opportunity but not a complete freedom-to-operate determination. A commercial entrant must map the product’s patent claims, the source of the product, the refurbishment process, and any replacement components.

How does Lexmark compare with Kirtsaeng and Quanta?

Case	Core rule	Commercial significance
Quanta Computer, Inc. v. LG Electronics, Inc.	Authorized sale of a component can exhaust patent rights in systems practicing the patent	Limited downstream patent control over sold components
Kirtsaeng v. John Wiley & Sons, Inc.	Copyright’s first-sale doctrine can apply to authorized foreign-made copies	Support for international exhaustion in copyright
Lexmark International v. Impression Products	Authorized domestic and foreign sales exhaust patent rights	Broad patent exhaustion for resale and importation

Quanta addressed exhaustion through an authorized component sale and reinforced the doctrine’s application to downstream combinations. [3] Kirtsaeng involved copyright, but its treatment of international sales influenced the broader exhaustion analysis. [2] Lexmark supplied the definitive Supreme Court rule for patent exhaustion in both domestic and international contexts.

Key Takeaways

• Lexmark v. Impression Products, No. 14-1617, was decided by the Supreme Court on June 30, 2017.
• An authorized domestic sale exhausts patent rights in the particular product sold.
• A contractual single-use or no-resale restriction may support a contract claim but not a patent-infringement claim against downstream users.
• An authorized foreign sale exhausts U.S. patent rights in the product sold.
• The ruling expanded aftermarket, remanufacturing, refurbishment, and parallel-import opportunities.
• Patent exhaustion does not authorize new manufacture, reconstruction of a patented article, infringement of separate component patents, or unauthorized use of patented methods.
• The decision did not change FDA exclusivity, Orange Book listing rules, Paragraph IV litigation, biosimilar litigation, or pharmaceutical patent terms.
• Life-sciences companies using patented devices, delivery systems, cartridges, or diagnostic platforms must separate exhaustion analysis from formulation, manufacturing, method-of-use, regulatory, contract, and trademark analysis.

FAQs About Lexmark v. Impression Products

Did Lexmark eliminate all post-sale restrictions?

No. It prevented the patent owner from enforcing a post-sale restriction through patent law. Contract remedies may remain available against a party that accepted the restriction.

Can a company import a patented product bought overseas?

Generally yes, if the foreign sale was authorized by the U.S. patent owner or an authorized seller. Separate trademark, contract, customs, regulatory, and product-liability issues may still apply.

Does patent exhaustion permit rebuilding a patented product?

Not automatically. Repair may be permissible, while reconstruction or manufacture of a new patented article may infringe.

Does Lexmark apply to biologics or biosimilars?

Only indirectly. The decision is a general patent-exhaustion authority and does not alter BPCIA procedures, biosimilar patent litigation, FDA approval standards, or biologic exclusivity.

Can a patent owner use a license instead of a sale to avoid exhaustion?

Potentially, if the transaction is legally a license rather than an authorized sale. Courts examine the substance of the transaction, the parties’ rights, possession, payment structure, and contractual terms.

References

1. Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 152, 137 S. Ct. 1523 (2017).

2. Kirtsaeng v. John Wiley & Sons, Inc., 568 U.S. 519 (2013).

3. Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008).